Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.39 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.39 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3709351 | 0.90 | CYP2C9 (0.51) | CYP2C9CYP3A4LRRK2ROCK2ROCK1 | |
| SCHEMBL2888193 | 0.84 | CYP3A4 (0.61) | CYP2C9CYP3A4LRRK2 | |
| SCHEMBL298849 | 0.79 | CYP2C9 (0.55) | CYP2C9CYP3A4 | |
| SCHEMBL3712294 | 0.78 | PARP1 (0.42) | CYP2C9 | |
| SCHEMBL298174 | 0.78 | CYP3A4 (0.61) | CYP2C9CYP3A4LRRK2 | |
| SCHEMBL3509976 | 0.77 | MAP2K1 (0.52) | CYP2C9LRRK2ROCK2 | |
| SCHEMBL1720729 | 0.76 | CYP2C9 (0.66) | CYP2C9CYP3A4 | |
| SCHEMBL3712853 | 0.75 | CYP2C9 (0.51) | CYP2C9CYP3A4 | |
| SCHEMBL25237394 | 0.75 | LRRK2 (0.42) | CYP2C9CYP3A4LRRK2ROCK2ROCK1 | |
| SCHEMBL3705714 | 0.75 | CYP3A4 (0.51) | CYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2C9 2176/4885CYP3A4 3611/4885LRRK2 1249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.